Preoperative Axillary Lymph Node Marking in Patients with Breast Cancer

Česká verzia

Authors: L. Dostálek; P. Šašková
Authors place of work: Gynekologicko-porodnická klinika, 1. LF a VFN v Praze
Published in the journal: Klin Onkol 2017; 30(6): 420-425
Category: Přehled
doi: https://doi.org/10.14735/amko2017420

Summary

Background:
Axillary dissection (AD) is an integral part of the surgical staging of breast cancer. This operation can be source of major long term complications, e. g., lymphedema. Reducing the radicality of these operations has been the subject of many clinical trials, especially those addressing the metastatic infiltration of axillary lymph nodes uncovered either by clinical staging or by sentinel lymph node (SLN) biopsy (when the clinical staging was negative). Exact clinical (mainly ultrasonographic) staging and marking of the lymph nodes detected by staging plays a key role in deciding the optimum clinical regimen.

Purpose:
Three possibilities were tested in clinical trials: The possibility of replacing the AD by radiotherapy in the case of tumorous infiltration of SLN, when clinical staging was negative; the possibility of omitting AD (in patients with positive clinical axillary staging) and replacing it with SLN biopsy after neoadjuvant chemotherapy; and the possibility of marking lymph nodes in axilla that were suspected of infiltration at the time of clinical staging.

Results:
The studies showed clear evidence that avoiding AD was safe in oncology patients who showed infiltration of axillary SLN and negative clinical staging. Despite the high false negativity of using SLN biopsies in patients with a positive clinical staging after neoadjuvant chemotherapy, this false negativity could be reduced by using lymph node marking. By implementing these methods, it should be possible to define exactly the group of patients in whom complete pathological remission occurs after neoadjuvant chemotherapy.

Key words:
breast neoplasms – axilla – lymph nodes

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
17. 4. 2017

Accepted:
2. 7. 2017

Zdroje

1. Lyman GH, Giuliano AE, Somerfield MR et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2010; 23 (30): 7703–7720. doi: 10.1200/JCO.2005.08.001.

2. Rauh C, Matthias W. Interdisziplinäre S3-Leitlinie für die Diagnostik 2013; Therapie und Nachsorge des Mammakarzinoms. [online]. Available from: http://leitlinienprogramm-onkologie.de/uploads/tx_sbdownloader/S3-Brustkrebs-v2012-OL-Langversion.pdf.

3. Gradishar WJ, Anderson BO, Balassanian R et al. Breast cancer, version 1.2016 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2016; 13 (12): 1475–1485.

4. Giuliano AE, Hunt KK, Ballman KV et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. Jama 2011; 305 (6): 569–575. doi: 10.1001/jama.2011.90.

5. Donker M, van Tienhoven G, Straver ME et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014; 15 (12): 1303–1310. doi: 10.1016/S1470-2045 (14) 70460-7.

6. Boughey JC, Suman VJ, Mittendorf EA et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. Jama 2013; 310 (14): 1455–1461. doi: 10.1001/jama.2013.278932.

7. Boughey JC, Ballman KV, Le-Petross HT et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0–T4, N1–N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg 2016; 263 (4): 802–807. doi: 10.1097/SLA.0000000000001375.

8. Kuehn T, Bauerfeind I, Fehm T et al. Sentinel-lymphnode biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncology 2013; 14 (7): 609–618. doi: 10.1016/S1470-2045 (13) 701 66-9.

9. Choy N, Lipson J, Porter C et al. Initial results with preoperative tattooing of biopsied axillary lymph nodes and correlation to sentinel lymph nodes in breast cancer patients. Ann Surg Oncol 2015; 22 (2): 377–382. doi: 10.1245/s10434-014-4034-6.

10. Plecha D, Bai S, Patterson H et al. Improving the accuracy of axillary lymph node surgery in breast cancer with ultrasound-guided wire localization of biopsy proven metastatic lymph nodes. Ann Surg Oncol 2015; 22 (13): 4241–4246. doi: 10.1245/s10434-015-4527-y.

11. Caudle AS, Yang WT, Krishnamurthy S et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 2016; 34 (10): 1072–1078. doi: 10.1200/JCO.2015.64.0094.

12. Donker M, Straver ME, Wesseling J et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg 2015; 261 (2): 378–382. doi: 10.1097/SLA.0000000000000558.

13. Straver ME, Loo CE, Alderliesten T et al. Marking the axilla with radioactive iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer. Br J Surg 2010; 97 (8): 1226–1231. doi: 10.1002/bjs.7073.

14. Vrtělová P, Coufal O, Fait V et al. Lymphoedema Following Regional Lymph Node Surgery for Breast Cancer. Klin Onkol 2017; 30 (1): 34–34. doi: 10.14735/amko201734.

15. Pavlista D, Eliska O. Relationship between the lymphatic drainage of the breast and the upper extremity: a postmortem study. Ann Surg Oncol 2012; 19 (11): 3410–3415. doi: 10.1245/s10434-012-2363-x.

16. Fleissig A, Fallowfield LJ, Langridge CI et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast cancer Res Treat 2006; 95 (3): 279–293. doi: 10.1007/s10549-005-9025-7.

17. Krag DN, Anderson SJ, Julian TB et al. Sentinel-lymphnode resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010; 11 (10): 927–933. doi: 10.1016/S1470-2045 (10) 70207-2.

18. Dominici LS, Negron Gonzalez VM, Buzdar AU et al. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer 2010; 116 (12): 2884–2889. doi: 10.1002/cncr.25152.

19. Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15 (7): 2483–2493. doi: 10.1200/JCO.1997.15.7.2483.

20. Kuerer HM, Sahin AA, Hunt KK et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 1999; 230 (1): 72–78.

21. Xing Y, Foy M, Cox DD et al. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. B J Surg 2006; 93 (5): 539–546. doi: 10.1002/bjs.5209.

22. Alvarez S, Añorbe E, Alcorta P el al. Role of sonography in the diagnosis of axillary lymph node metastases in breast cancer: a systematic review. AJR Am J Roentgenol 2006; 186 (5): 1342–1348. doi: 10.2214/AJR.05.0936.

23. Lee B, Lim AK, Krell J et al. The efficacy of axillary ultrasound in the detection of nodal metastasis in breast cancer. AJR Am J Roentgenol 2013; 200 (3): W314–W320. doi: 10.2214/AJR.12.9032.

24. Abe H, Schacht D, Sennett CA et al. Utility of preoperative ultrasound for predicting pN2 or higher stage axillary lymph node involvement in patients with newly diag-nosed breast cancer. AJR Am J Roentgenol 2013; 200 (3): 696–702. doi: 10.2214/AJR.12.9036.

25. Schipper RJ, van Roozendaal LM, de Vries B et al. Axillary ultrasound for preoperative nodal staging in breast cancer patients: is it of added value? The Breast 2013; 22 (6): 1108–1113. doi: 10.1016/j.breast.2013.09.002.

26. Neal CH, Daly CP, Nees AV et al. Can Preoperative Axillary US Help Exclude N2 and N3 Metastatic Breast Cancer? Radiology 2010; 257 (2): 335–341. doi: 10.1148/radiol.10100296.

27. McGhan LJ, McKeever SC, Pockaj BA et al. Radioactive seed localization for nonpalpable breast lesions: review of 1,000 consecutive procedures at a single institution. Ann Surg Oncol 2011; 18 (11): 3096–3101. doi: 10.1245/s10434-011-1910-1.

28. Caudle AS, Yang WT, Mittendorf EA et al. Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial. JAMA Surg 2015; 150 (2): 137–143. doi: 10.1001/jamasurg.2014.1086.